Table of Content


1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Rising Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Hematology
5.1.4 Immuno Diagnostics
5.1.5 Other Types
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Other Applications
5.5 By End User
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals & Clinics
5.5.3 Other End Users


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Arkray Inc.
6.1.3 Becton, Dickinson and Company
6.1.4 bioM?rieux SA
6.1.5 Bio-Rad Laboratories Inc.
6.1.6 Danaher Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Transasia Bio-Medicals Ltd
6.1.9 Sysmex Corporation
6.1.10 Thermo Fisher Scientific


7 MARKET OPPORTUNITIES AND FUTURE TRENDS